Your browser doesn't support javascript.
loading
Exploring monitoring strategies for population surveillance of HPV vaccine impact using primary HPV screening.
Velentzis, Louiza S; Hawkes, David; Caruana, Michael; Brotherton, Julia Ml; Smith, Megan A; Roeske, Lara; Karim, Khurram A; Garland, Suzanne M; Wrede, C David; Tan, Jeffery; Wheeler, Cosette; Castle, Philip E; Saville, Marion; Canfell, Karen.
Afiliação
  • Velentzis LS; The Daffodil Centre, The University of Sydney, a Joint venture with Cancer Council NSW, Sydney, NSW, Australia; Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: louizav@nswcc.org.au.
  • Hawkes D; Australian Centre for the Prevention of Cervical Cancer, 265 Faraday Street, Carlton South, Victoria, Australia; Department of Biochemistry and Pharmacology, University of Melbourne, Victoria, Australia; Department of Pathology, University of Malaya, Kuala Lumpur, Malaysia.
  • Caruana M; The Daffodil Centre, The University of Sydney, a Joint venture with Cancer Council NSW, Sydney, NSW, Australia.
  • Brotherton JM; Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia; Australian Centre for the Prevention of Cervical Cancer, 265 Faraday Street, Carlton South, Victoria, Australia; Department of Obstetrics and Gynaecology, University of Malaya, Kuala Lumpur 506
  • Smith MA; The Daffodil Centre, The University of Sydney, a Joint venture with Cancer Council NSW, Sydney, NSW, Australia.
  • Roeske L; Royal Australian College of General Practitioners, East Melbourne, Victoria, Australia.
  • Karim KA; Australian Centre for the Prevention of Cervical Cancer, 265 Faraday Street, Carlton South, Victoria, Australia.
  • Garland SM; Infection and Immunity, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia; Centre Women's Infectious Diseases Research, Royal Women's Hospital, Melbourne, Victoria, Australia.
  • Wrede CD; Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia; Department of Oncology & Dysplasia, Royal Women's Hospital, Melbourne, Victoria, Australia.
  • Tan J; Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria, Australia; Department of Oncology & Dysplasia, Royal Women's Hospital, Melbourne, Victoria, Australia.
  • Wheeler C; University of New Mexico Cancer Center, Albuquerque, NM, USA.
  • Castle PE; Division of Cancer Prevention, National Cancer Institute, NIH, Rockville, MD, USA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA.
  • Saville M; Australian Centre for the Prevention of Cervical Cancer, 265 Faraday Street, Carlton South, Victoria, Australia; Department of Obstetrics and Gynaecology, University of Malaya, Kuala Lumpur 50603, Malaysia.
  • Canfell K; The Daffodil Centre, The University of Sydney, a Joint venture with Cancer Council NSW, Sydney, NSW, Australia.
Tumour Virus Res ; 15: 200255, 2023 06.
Article em En | MEDLINE | ID: mdl-36736490
ABSTRACT
Australia's cervical screening program transitioned from cytology to HPV-testing with genotyping for HPV16/18 in Dec'2017. We investigated whether program data could be used to monitor HPV vaccination program impact (commenced in 2007) on HPV16/18 prevalence and compared estimates with pre-vaccination benchmark prevalence. Pre-vaccination samples (2005-2008) (n = 1933; WHINURS), from 25 to 64-year-old women had been previously analysed with Linear Array (LA). Post-vaccination samples (2013-2014) (n = 2989; Compass pilot), from 25 to 64-year-old women, were analysed by cobas 4800 (cobas), and by LA for historical comparability. Age standardised pre-vaccination HPV16/18 prevalence was 4.85% (95%CI3.81-5.89) by LA; post-vaccination estimates were 1.67% (95%CI1.21-2.13%) by LA, 1.49% (95%CI1.05-1.93%) by cobas, and 1.63% (95%CI1.17-2.08%) for cobas and LA testing of non-16/18 cobas positives (cobas/LA). Age-standardised pre-vaccination oncogenic HPV prevalence was 15.70% (95%CI13.79-17.60%) by LA; post-vaccination estimates were 9.06% (95%CI8.02-10.09%) by LA, 8.47% (95%CI7.47-9.47%) by cobas and cobas/LA. Standardised rate ratios between post-vs. pre-vaccination rates were significantly different for HPV16/18, non-16/18 HPV and oncogenic HPV 0.34 (95%CI0.23-0.50), 0.68 (95%CI0.55-0.84) and 0.58 (95%CI0.48-0.69), respectively. Additional strategies (LA for all cobas positives; combined cobas and LA results on all samples) had similar results. If a single method is applied consistently, it will provide important data on relative changes in HPV prevalence following vaccination.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Female / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article